MOSCOW (Reuters) – The Kremlin on Thursday said there were technological differences between Moscow and the European Medicines Agency (EMA) regarding the completeness of paperwork submitted for the certification of Russia’s Sputnik V vaccine.
The EU drug regulator is unlikely to decide whether to approve Sputnik V until at least the first quarter of 2022 because some data needed for the review was still missing, a source with knowledge of the matter told Reuters.
(Reporting by Gleb Stolyarov; Writing by Alexander Marrow; Editing by Katya Golubkova)
